Publication
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
Journal Paper/Review - May 18, 2022
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Loibl, S
30
0
Untch, M
19
0
Burchardi, N
6
0
Huober, Jens
chief physicianBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
297
12
Sinn, B V
4
0
Blohmer, J-U
7
0
Grischke, E-M
4
0
Furlanetto, J
4
0
Tesch, H
9
0
Hanusch, C
9
0
Engels, K
5
0
Rezai, M
6
0
Jackisch, C
17
0
Schmitt, W D
5
0
von Minckwitz, G
14
0
Thomalla, J
3
0
Kümmel, S
6
0
Rautenberg, B
2
0
Fasching, P A
14
0
Weber, K
3
0